As AI achieves impressive milestones, like assisting in creating a cancer vaccine, the public conversation immediately discounts the achievement. The goalposts shift from "AI helped solve a problem" to demanding a fully autonomous, one-shot solution. This pattern of escalating expectations obscures the real, incremental progress being made.
AI's true power in science isn't autonomous discovery, but process compression. It acts as an expert guide, allowing motivated individuals to navigate complex fields like drug discovery and assemble workflows that once required multiple specialized teams, blurring the line between professional research and individual effort.
Futurist Freeman Dyson predicted biotechnology would follow computing's path, moving from large institutions to individual creators. AI is accelerating this shift by lowering the cognitive barrier to entry, potentially making biological design an accessible, decentralized craft. This counters the dominant narrative of AI as a purely centralizing force.
Ben Thompson argues the shift from simple chatbots to AI agents creates an exponential, non-speculative demand for compute. Agents automate complex, multi-step tasks, driving constant usage that justifies the massive capex investments by hyperscalers. This suggests the current spending is based on real demand, not bubble-fueled speculation.
The greatest productivity gain from AI in large companies won't be simple job elimination. Instead, AI agents will replace the "hard to manage and motivate human cogs" that create organizational friction. This reduces coordination costs and allows a company's key value-driving employees to execute far more effectively.
In capital-intensive markets like AI, capital is a competitive weapon. If fundraising feels easy, it's a signal you weren't aggressive enough. Kalanick's philosophy suggests you should have pushed for a much larger round to create a significant moat against competitors, treating capital as a strategic advantage.